Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Candel Therapeutics (CADL) Return on Capital Employed (2021 - 2023)

Candel Therapeutics' Return on Capital Employed history spans 3 years, with the latest figure at 0.82% for Q3 2023.

  • For Q3 2023, Return on Capital Employed fell 41.0% year-over-year to 0.82%; the TTM value through Sep 2023 reached 0.82%, down 41.0%, while the annual FY2022 figure was 0.45%, 1.0% down from the prior year.
  • Return on Capital Employed for Q3 2023 was 0.82% at Candel Therapeutics, down from 0.66% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.29% in Q4 2021 and bottomed at 0.82% in Q3 2023.
  • The 3-year median for Return on Capital Employed is 0.41% (2022), against an average of 0.48%.
  • The largest annual shift saw Return on Capital Employed changed 0bps in 2022 before it tumbled -41bps in 2023.
  • A 3-year view of Return on Capital Employed shows it stood at 0.29% in 2021, then crashed by -55bps to 0.46% in 2022, then plummeted by -79bps to 0.82% in 2023.
  • Per Business Quant, the three most recent readings for CADL's Return on Capital Employed are 0.82% (Q3 2023), 0.66% (Q2 2023), and 0.53% (Q1 2023).